Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBITDA (2016 - 2026)

Perspective Therapeutics' EBITDA history spans 17 years, with the latest figure at -$28.3 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 29.54% to -$28.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$120.0 million, a 20.36% decrease, with the full-year FY2025 number at -$113.6 million, down 24.95% from a year prior.
  • EBITDA hit -$28.3 million in Q1 2026 for Perspective Therapeutics, up from -$39.8 million in the prior quarter.
  • Over the last five years, EBITDA for CATX hit a ceiling of -$1.4 million in Q1 2022 and a floor of -$45.0 million in Q4 2024.
  • Historically, EBITDA has averaged -$16.9 million across 5 years, with a median of -$13.0 million in 2024.
  • Biggest five-year swings in EBITDA: plummeted 609.38% in 2023 and later increased 11.45% in 2025.
  • Tracing CATX's EBITDA over 5 years: stood at -$5.6 million in 2022, then tumbled by 107.72% to -$11.7 million in 2023, then crashed by 285.27% to -$45.0 million in 2024, then increased by 11.45% to -$39.8 million in 2025, then grew by 29.0% to -$28.3 million in 2026.
  • Business Quant data shows EBITDA for CATX at -$28.3 million in Q1 2026, -$39.8 million in Q4 2025, and -$27.9 million in Q3 2025.